Understand the source comparison
Kisspeptin vs Other Peptides: Research Comparison
Kisspeptin-10 GnRH stimulation via GPR54 activation GPR54 (KISS1R) Yes. Mimics natural pulsatile release 0.01–10 nmol/kg (IV or SC bolus) Best suited for reproductive hormone research and HPG axis studies. No overlap with GH or tissue repair pathways GHRP-2 Gr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Kisspeptin-10
- GnRH stimulation via GPR54 activation
- GPR54 (KISS1R)
- Yes. Mimics natural pulsatile release
- 0.01–10 nmol/kg (IV or SC bolus)
- Best suited for reproductive hormone research and HPG axis studies. No overlap with GH or tissue repair pathways
- GHRP-2
- Growth hormone secretagogue via ghrelin receptor agonism
- GHS-R1a
- Yes. Pulsatile GH release pattern matters
- 1–3 mcg/kg (SC or IV bolus)
- Direct GH stimulation without cortisol or prolactin elevation. Overlaps with MK-677 but shorter half-life
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic. Sustained GH and IGF-1 elevation
- No. Provides continuous receptor activation
- 10–25 mg/day (oral)
- Longer-acting than GHRP-2, eliminates injection requirement, but continuous activation may reduce receptor sensitivity over time
- BPC-157
- Angiogenesis promotion and tissue repair via VEGF upregulation
- No single receptor. Acts on multiple growth factor pathways
- No
- 200–500 mcg/day (SC or oral)
- Purely tissue repair focused. No hormonal or metabolic signaling overlap with kisspeptin or GH peptides
- TB-500
- Actin regulation and cell migration for wound healing
- Binds intracellular actin. Not a receptor-mediated pathway
- 2–5 mg twice weekly (SC)
- Potent for soft tissue injury models but entirely distinct from endocrine peptides
- CJC-1295 (DAC)
- Long-acting GHRH analog. Sustained GH elevation
- GHRH receptor
- No. Drug affinity complex extends half-life to 6–8 days
- 30–60 mcg/kg weekly (SC)
- Sustained GH release useful for metabolic studies but lacks the pulsatility of GHRP-2. Different application than kisspeptin